EyeGate Pharmaceuticals, Inc. (EYEG) , a stock from Biotechnology Industry, has a value of $0.63 per share, noted a price change of 7.71% in recent trade close. The price to sales ratio is 27.18. The lower price P/S ratio indicates attractive the investment. A low P/S can also be effective in valuing growth stocks that have suffered a temporary setback. A low P/S ratio may indicate possible undervaluation, while a ratio that is significantly above the average may suggest overvaluation. Abbreviated as the P/S ratio or PSR, this ratio is also known as a “sales multiple” or “revenue multiple.”
Annual earnings per share (EPS) growth noted at 0.10% in past 5 Years and The company is estimating to achieve earnings per share (EPS) growth of 38.60% in this year .
The stock has P/B of 2.03. The price-to-book ratio (P/B Ratio) is a ratio used to compare a stock’s market value to its book value. It is calculated by dividing the current closing price of the stock by the latest quarter’s book value per share. A lower P/B ratio could mean that the stock is undervalued. However, it could also mean that something is fundamentally wrong with the company. As with most ratios, be aware that this varies by industry. This ratio also gives some idea of whether you’re paying too much for what would be left if the company went bankrupt immediately.
Analysts mean Recommendation on a stock is noted at 2.00. Analyst Recommendation is an outlook of a stock-market analyst on a stock. Rating Scale: 1.0 represent “Strong Buy” and 2.0 signify “Buy” 3.0 while shows “Hold”. 4.0 display “Sell” and 5.0 reveal “Strong Sell” rating.
The performance for week is 27.42% and the performance for quarter is at -4.53%. The performance for month is 28.59% and the performance for half year is -42.19%. Its monthly volatility value of 12.30% and volatility for the week is valued at 12.80%. The performance for Year to Date (YTD) is -41.11%.
32.00% shares of the company possessed by Institutional Investors. The net percent change held by Institutional Investors has seen a change of -3.65% in last three month period. Insiders own 5.40% of EyeGate Pharmaceuticals, Inc. (EYEG) shares.
A ROI of 695.60% for the company evaluates and compares the efficiency of the various numbers of investments relative to the cost of investments.